Brainomix Advances Stroke Care with Landmark FDA Clearance

Brainomix United States of America Illinois England United Kingdom

Brainomix 360 unlocks expert-level insights from universally available non-contrast CT scans, helping stroke networks expand access to life-changing treatmentsto register for free.

About Brainomix

Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spinout from the University of Oxford, Brainomix is an expanding commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 20 countries. A private company, backed by leading healthtech investors, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving increased treatment rates and improving functional independence for patients.

To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, LinkedIn and Facebook.

Contacts

Jeff Wyrtzen, Chief Marketing & Business Development Officer
[e-mail]
T [phone]

Media Enquiries

Charles Consultants
Sue Charles
[e-mail]
M [phone]

Logo - https://mma.prnewswire.com/media/1989193/5254734/Brainomix_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/brainomix-advances-stroke-care-with-landmark-fda-clearance-302421960.html

@ prnewswire.co.uk